Journal of Clinical Oncology · 2024 · 89 citations · 29 references
Life SciencesHematologyImmunologyStem Cell TransplantationTransplant ImmunologyTransplant PharmacotherapyAllogeneic Stem Cell TransplantationDonor MatchingGraft-versus-host DiseaseHistocompatibilityHla MatchingHla TypingCalcineurin Inhibitor ImmunosuppressionHla Antigen MatchingHla Matching In TransplantationHla-dq MatchingHla-dr MatchingMatched Unrelated Donor TransplantationPost-transplant CyclophosphamideUnrelated Donation
PURPOSE Access to allogeneic hematopoietic cell transplantation (HCT) remains limited among persons of non-European ancestry if human leukocyte antigen (HLA) matching is required. We evaluated whether post-transplant cyclophosphamide (PTCy)–based graft-versus-host disease (GVHD) prophylaxis improved HCT outcomes with HLA-matched unrelated donor (MUD) and mismatched unrelated donor (MMUD) HCT when compared with calcineurin inhibitor (CNI)–based prophylaxis. METHODS Three-year overall survival (OS) and GVHD-free, relapse-free survival (GRFS) were compared between adult recipients undergoing initial MUD or single HLA locus MMUD HCT with either PTCy- or CNI-based prophylaxis who were reported to the Center for International Blood and Marrow Transplant Research between 2017 and 2021. RESULTS Included were 10,025 HCT recipients (7,272 recipients of MUD with CNI, 1,681 MUD with PTCy, 613 MMUD with CNI, and 459 MMUD with PTCy) who underwent HCT for acute leukemia (70.9%) or myelodysplastic syndromes (29.2%). Median patient age was 60.7 years (range, 18.0-82.7) and median follow-up was 36.6 (range, 3.0-77.8) months. When compared with MUD HCT with PTCy, MMUD HCT with PTCy had similar OS (hazard ratio [HR], 0.96 [95% CI, 0.823 to 1.11]; P = .60) and GRFS (HR, 0.90 [0.79 to 1.02]; P = .1). When compared with MUD HCT with CNI, OS was improved after MUD HCT with PTCy (HR, 0.88 [0.80 to 0.96]; P = .004) and GRFS was improved with PTCy after either MUD (HR, 0.61 [0.57 to 0.66]; P < .0001) or MMUD (HR, 0.68 [0.60 to 0.76]; P < .0001) HCT. Benefit from PTCy was independent of patient ancestry. Global registry level analysis demonstrated that inclusion of MMUD increased donor availability regardless of recipient ancestry. CONCLUSION Use of PTCy results in comparable OS and GRFS using either MUD or MMUD HCT, expanding access to HCT for patients from all racial and ethnic ancestry groups.
29
The Statistical Analysis of Failure Time Data.
Murray Aitkin, John D. Kalbfleisch, Ross L. Prentice · Biometrics · 1981 · 10K citations
Madan Jagasia, Hildegard Greinix, Mukta Arora et al. · Biology of Blood and Marrow Transplantation · 2014 · 5.4K citations · Full text
Leo Luznik, Paul V. O’Donnell, Heather J. Symons et al. · Biology of Blood and Marrow Transplantation · 2008 · 1.9K citations · Full text
Medicine, Hematology, Oncology +16